EDX Medical develops digital diagnostic solutions for the rapid detection and characterization of major diseases, focusing on oncology, cardiology, and infectious diseases. The company combines molecular biology laboratory work with point-of-care devices to deliver precise patient test results. These trusted diagnostic solutions enable healthcare professionals to implement personalized treatment strategies for improved patient outcomes.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Detecting major diseases like cancer, heart disease, and infectious diseases often relies on traditional laboratory processing, which can be time-consuming and may delay personalized treatment plans. Traditional diagnostic methods may not provide healthcare professionals with rapid, accurate measurements of disease markers at the point of care.
Solution
EDX Medical Group develops and commercializes point-of-care diagnostic tests that leverage molecular biology and digital technologies for the rapid detection and characterization of major diseases. These solutions enable personalized treatment by providing healthcare professionals with accurate disease marker measurements within minutes, reducing reliance on traditional laboratory processing. EDX Medical offers a range of tests for early detection of cancer, infections, and cardiovascular conditions, combining biological and digital technologies to set new standards in risk assessment and personal diagnosis. The company also partners with other organizations to distribute key products and develop clinical-grade assays.
Target Audience
The primary target audience includes healthcare professionals and organizations seeking reliable, high-performance diagnostic tools for predicting and managing diseases on a personalized basis.
Features
- Point-of-care tests deliver results within minutes, enabling faster clinical decision-making.
- Molecular biology testing laboratory performs PCR technologies.
- Development of tests capable of accurately measuring multiple disease markers on a single device.
- Secure digital services including test reader and App for real-time reporting on mobile devices, data analytics tools and government / corporate reporting.
- Disease surveillance solutions for rapid identification of new diseases and variants.
- Bowel cancer 'super test' for early detection of disease.
- ARDP (Acute Respiratory Distress & Pneumonia) ICU test for early, definitive detection.
- Multiple Biomarker 5FU Pharmacogenomic Test for patients receiving fluoropyrimidine-based chemotherapies.
- Point of care multiplex sepsis test for detection of bacterial or viral infections.
- Comprehensive Tumour Profiling (MI Profile) using whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis.
- cResponse™ for assessing and predicting the effectiveness of cancer treatments on tumor tissue.
- Tumour Biopsy Molecular Profiling (MI Tumor Seek) using Next-Generation Sequencing (NGS).
- Testicular Cancer test
- TC100 for early detection of testicular cancer.
- Prostate cancer screening test using blood and urine samples.